Multifaceted Modulation of SIRT1 in Cancer and Inflammation

Hui Yang1, Yujing Bi2, Lixiang Xue3

  • 1Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai China; Biotherapy Research Center, Institute of Immunobiology, Fudan University.

Insights

Sirtuin 1 (SIRT1) is a key enzyme regulating inflammation and cancer. It influences immune responses and acts as both an oncoprotein and tumor suppressor, offering potential for novel cancer therapies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Immunology

Background:

  • Sirtuin 1 (SIRT1) is a NAD+-dependent deacetylase involved in numerous cellular processes.
  • SIRT1 targets both histone and non-histone proteins, impacting signaling pathways.
  • Evidence links SIRT1 to lifespan, DNA repair, metabolic stress, inflammation, and cancer.

Purpose of the Study:

  • To review the role of SIRT1 in immune responses.
  • To discuss the dual role of SIRT1 in tumorigenesis.
  • To explore SIRT1's impact on the tumor microenvironment for therapeutic insights.

Main Methods:

  • Literature review of studies on SIRT1 function.
  • Analysis of SIRT1's deacetylase activity on various substrates.
  • Examination of SIRT1's involvement in inflammatory and cancer pathways.

Main Results:

  • SIRT1 modulates immune cell responses by deacetylating transcription factors.
  • SIRT1 exhibits context-dependent roles in cancer, acting as an oncoprotein or tumor suppressor.
  • SIRT1 affects both cancer cells and immune cells within the tumor microenvironment.

Conclusions:

  • SIRT1 is a critical regulator of inflammation and immunity.
  • Understanding SIRT1's complex role in cancer is crucial for developing targeted therapies.
  • SIRT1-based strategies may offer new avenues for cancer treatment by modulating the tumor microenvironment.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
8.0K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.5K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.3K